TIDMHIK
RNS Number : 8299E
Hikma Pharmaceuticals Plc
15 March 2022
Hikma Pharmaceuticals PLC - EIP C Vesting
LONDON, 15 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces
that the following Persons Discharging Managerial Responsibility
("PDMR") have received shares as a result of the vesting of their
conditional share awards which were granted on 12 March 2019 under
the 2014 Executive Incentive Plan ("EIP") Element C.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 38,862
d) Aggregated information
* Volume
38,862
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Siggi Olafsson
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. 16,299
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 26,377
Price(s): GBP19.88
Volume(s): 16,299
d) Aggregated information
* Volume
42,676
GBP19.88
* Price GBP324,024.12
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Siggi Olafsson
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
a bespoke arrangement in respect of the first
year of service only that operates on the same
basis as Element C of the 2014 Executive Incentive
Plan (EIP). 27,498 Shares were sold to cover
tax and the remainder were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 44,502
Price(s): GBP19.88
Volume(s): 27,498
d) Aggregated information
* Volume
72,000
GBP19.88
* Price GBP546,660.24
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 26,514
d) Aggregated information
* Volume
26,514
GBP0.00
* Price GBP0.00
Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 23,030
d) Aggregated information
* Volume
23,030
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 12,064
d) Aggregated information
* Volume
12,064
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 19,195
d) Aggregated information
* Volume
19,195
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. All
Shares were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 17,710
d) Aggregated information
* Volume
17,710
GBP0.00
* Price GBP0.00
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Brian Hoffmann
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. 4,310
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 6,975
Price(s): GBP19.88
Volume(s): 4,310
d) Aggregated information
* Volume
11,285
GBP19.88
* Price GBP85,682.80
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Susan Ringdal
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. 4,820
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 5,383
Price(s): GBP19.88
Volume(s): 4,820
d) Aggregated information
* Volume
10,203
GBP19.88
* Price GBP95,821.60
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Henriette Nielsen
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status PDMR
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the Shares acquired from the vesting of conditional
transaction awards on
14 March 2022 under the EIP Element C. 2,670
Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 4,320
Price(s): GBP19.88
Volume(s): 2,670
d) Aggregated information
* Volume
6,990
GBP19.88
* Price GBP53,079.60
* Total
e) Date of the transaction 14 March 2022
f) Place of the London Stock Exchange (XLON)
transaction
Peter Speirs
Company Secretary, responsible for releasing this
announcement
+44 (0) 20 7399 2760
15 March 2022
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBGGDXRUBDGDU
(END) Dow Jones Newswires
March 15, 2022 06:58 ET (10:58 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
